Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics completed enrollment of the Phase 2b open-label dose confirmation portion of the registrational THRIVE-3 trial of IV Choline Chloride in intestinal failure patients dependent on parenteral support. The Phase 2b cohort includes 24 patients, with interim results from the dosing cohort on track to be reported in the fourth quarter of 2026; the Phase 3 portion will enroll roughly 100 patients with plasma choline elevation as the primary endpoint.
Key figures
- Drug Name
- IV Choline Chloride
- Phase Of Trial
- Phase 2b/3 (THRIVE-3)
- Phase2b enrollment
- 24
- Interim data timing
- 4Q 2026
- Phase3 planned enrollment
- approximately 100 patients
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.